

IgA Nephropathy Reference Literature

Last updated: April 2024

1. Stamellou E, Seikrit C, Tang SCW, Boor P, Tesař V, Floege J, Barratt J, Kramann R. **IgA nephropathy**. Nat Rev Dis Primers. 2023 Nov 30;9(1):67. doi: 10.1038/s41572-023-00476-9. PMID: 38036542.
2. El Karoui K, Fervenza FC, De Vriese AS. **Treatment of IgA Nephropathy: A Rapidly Evolving Field**. J Am Soc Nephrol. 2024 Jan 1;35(1):103-116. doi: 10.1681/ASN.0000000000000242. Epub 2023 Sep 29. PMID: 37772889; PMCID: PMC10786616.
3. Willey CJ, Coppo R, Schaefer F, Mizerska-Wasiak M, Mathur M, Schultz MJ. **The incidence and prevalence of IgA nephropathy in Europe**. Nephrol Dial Transplant. 2023 Sep 29;38(10):2340-2349. doi: 10.1093/ndt/gfad082. PMID: 37156519; PMCID: PMC10539204.
4. Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, Steenkamp R, Wong K, Turner AN, Wang K, Gale DP, Barratt J. **Long-Term Outcomes in IgA Nephropathy**. Clin J Am Soc Nephrol. 2023 Jun 1;18(6):727-738. doi: 10.2215/CJN.0000000000000135. Epub 2023 Apr 13. PMID: 37055195; PMCID: PMC10278810.
5. Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małeckı R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. **Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial**. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. PMID: 37931634.
6. Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. **Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial**. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. PMID: 37015244.
7. Liu P, Lassén E, Nair V, Berthier CC, Suguro M, Sihlbom C, Kretzler M, Betsholtz C, Haraldsson B, Ju W, Ebefors K, Nyström J. **Transcriptomic and Proteomic Profiling Provides Insight into Mesangial Cell Function in IgA Nephropathy**. J Am Soc Nephrol. 2017 Oct;28(10):2961-2972. doi: 10.1681/ASN.2016101103. Epub 2017 Jun 23. PMID: 28646076; PMCID: PMC5619958.
8. Levin A, Schwarz A, Hulkko J, He L, Sun Y, Barany P, Bruchfeld A, Herthelius M, Wennberg L, Ebefors K, Patrakka J, Betsholtz C, Nyström J, Mölne J, Hultenby K, Witas A, Wernerson A. **The role of dendrin in IgA nephropathy**. Nephrol Dial Transplant. 2023 Feb 13;38(2):311-321. doi: 10.1093/ndt/gfac208. PMID: 35767852; PMCID: PMC9923709.
9. Sallustio F, Picerno A, Cimmarusti MT, Montenegro F, Curci C, De Palma G, Sivo C, Annese F, Fontò G, Stasi A, Pesce F, Tafuri S, Di Leo V, Gesualdo L. **Elevated levels of IL-6 in IgA nephropathy patients are induced by an epigenetically driven mechanism modulated by viral and bacterial**

RNA. Eur J Intern Med. 2023 Dec;118:108-117. doi: 10.1016/j.ejim.2023.07.045. Epub 2023 Aug 5. PMID: 37550110.

10. Sallustio F, Picerno A, Montenegro F, Cimmarusti MT, Di Leo V, Gesualdo L. **The Human Virome and Its Crosslink with Glomerulonephritis and IgA Nephropathy.** Int J Mol Sci. 2023 Feb 15;24(4):3897. doi: 10.3390/ijms24043897. PMID: 36835304; PMCID: PMC9964221.
11. Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NeflgArd Trial Investigators. **Results from part A of the multi-center, double-blind, randomized, placebo-controlled NeflgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.** Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. PMID: 36270561.
12. Deng X, Luo Y, Lu M, Lin Y, Ma L. **Identification of GMFG as a novel biomarker in IgA nephropathy based on comprehensive bioinformatics analysis.** Heliyon. 2024 Apr 2;10(7):e28997. doi: 10.1016/j.heliyon.2024.e28997. PMID: 38601619; PMCID: PMC11004809.
13. Zhao C, Zhang M, Zhao L, Sun W. **From genomic insights to clinical hope: Targeting NEU1 in IgA nephropathy.** Int Immunopharmacol. 2024 Apr 9;132:112051. doi:10.1016/j.intimp.2024.112051. Epub ahead of print. PMID: 38599098.
14. Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh KH, Sahay M, Suzuki Y, Wong MG, Yarbrough J, Xia J, Pereira BJG; ENVISION Trial Investigators Group. **A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.** N Engl J Med. 2024 Jan 4;390(1):20-31. doi: 10.1056/NEJMoa2305635. Epub 2023 Nov 2. PMID: 37916620.
15. Lafayette R, Barbour S, Israni R, Wei X, Eren N, Floege J, Jha V, Kim SG, Maes B, Phoon RK, Singh H, Tesar V, Lin CJ, Barratt J. **A Phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.** Kidney Int. 2024 Mar 27:S0085-2538(24)00236-9. doi: 10.1016/j.kint.2024.03.012. Epub ahead of print. PMID: 38552841.
16. Gan T, Qu LX, Qu S, Qi YY, Zhang YM, Wang YN, Li Y, Liu LJ, Shi SF, Lv JC, Zhang H, Peng YJ, Zhou XJ. **Unveiling biomarkers and therapeutic targets in IgA nephropathy through large-scale blood transcriptome analysis.** Int Immunopharmacol. 2024 Mar 28;132:111905. doi: 10.1016/j.intimp.2024.111905. Epub ahead of print. PMID: 38552291.
17. Ying Y, Wang L, Ma S, Zhu Y, Ye S, Jiang N, Zhao Z, Zheng C, Shentu Y, Wang Y, Li D, Zhang J, Chen C, Huang L, Yang D, Zhou Y. **An enhanced machine learning approach for effective prediction of IgA nephropathy patients with severe proteinuria based on clinical data.** Comput Biol Med. 2024 Mar 24;173:108341. doi: 10.1016/j.compbimed.2024.108341. Epub ahead of print. PMID: 38552280.
18. Gleeson PJ, Benech N, Chemouny J, Metallinou E, Berthelot L, da Silva J, Bex-Coudrat J, Boedec E, Canesi F, Bounaix C, Morelle W, Moya-Nilges M, Kenny J, O'Mahony L, Saveanu L, Arnulf B, Sannier A, Daugas E, Vrtovnik F, Lepage P, Sokol H, Monteiro RC. **The gut microbiota posttranslationally modifies IgA1 in autoimmune glomerulonephritis.** Sci Transl Med. 2024 Mar 27;16(740):eadl6149. doi: 10.1126/scitranslmed.adl6149. Epub 2024 Mar 27. PMID: 38536935.
19. Luo R, Qian D, Yang D, Cheng Y, Li J, Liu L, Li Y, Lei Q, Chang X, Liu Y, Xu G, Ge S. **Circulating soluble CD30 is associated with renal tertiary lymphoid structures and the progression of IgA**

- nephropathy.** Clin Chim Acta. 2024 Mar 24;557:117888. doi: 10.1016/j.cca.2024.117888. Epub ahead of print. PMID: 38527714.
20. Vaz de Castro PAS, Amaral AA, Almeida MG, Selvaskandan H, Barratt J, Simões E Silva AC. **Examining the association between serum galactose-deficient IgA1 and primary IgA nephropathy: a systematic review and meta-analysis.** J Nephrol. 2024 Mar 1. doi: 10.1007/s40620-023-01874-8. Epub ahead of print. PMID: 38427309.
 21. Duan ZY, Bu R, Liang S, Chen XZ, Zhang C, Zhang QY, Li JJ, Chen XM, Cai GY. **Urinary miR-185-5p is a biomarker of renal tubulointerstitial fibrosis in IgA nephropathy.** Front Immunol. 2024 Feb 15;15:1326026. doi: 10.3389/fimmu.2024.1326026. PMID: 38426107; PMCID: PMC10902439.
 22. Zhu Y, He H, Sun W, Wu J, Xiao Y, Peng Y, Hu P, Jin M, Liu P, Zhang D, Wu J, Xie T, Huang L, He W, Wei M, Wang L, Xu X, Tang Y. **IgA nephropathy: gut microbiome regulates the production of hypoglycosylated IgA1 via the TLR4 signaling pathway.** Nephrol Dial Transplant. 2024 Feb 24:gfae052. doi: 10.1093/ndt/gfae052. Epub ahead of print. PMID: 38402460.
 23. Lim RS, Yeo SC, Barratt J, Rizk DV. **An Update on Current Therapeutic Options in IgA Nephropathy.** J Clin Med. 2024 Feb 7;13(4):947. doi: 10.3390/jcm13040947. PMID: 38398259; PMCID: PMC10889409.
 24. Zhang Q, Zhao Y, Luo Y, Guo S, Hou H, Han X, Zhou Y. **Urinary exosomal miRNA-451a can be used as a potential noninvasive biomarker for diagnosis, reflecting tubulointerstitial damage and therapeutic response in IgA nephropathy.** Ren Fail. 2024 Dec;46(1):2319326. doi: 10.1080/0886022X.2024.2319326. Epub 2024 Feb 20. PMID: 38379319; PMCID: PMC10883088.
 25. Cheung CK, Barratt J, Liew A, Zhang H, Tesar V, Lafayette R. **The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies.** Front Nephrol. 2024 Feb 1;3:1346769. doi: 10.3389/fneph.2023.1346769. PMID: 38362118; PMCID: PMC10867227.
 26. Miao J, Duriseti P, Radhakrishnan Y, Vaughan L, Fervenza FC, Zand L. **Mycophenolate Mofetil and Steroid for Treatment of Patients With IgA Nephropathy.** Kidney Int Rep. 2023 Oct 20;9(1):182-185. doi: 10.1016/j.ekir.2023.10.015. PMID: 38312785; PMCID: PMC10831348.
 27. Tang C, Chen P, Si FL, Lv JC, Shi SF, Zhou XJ, Liu LJ, Zhang H. **Time-Varying Proteinuria and Progression of IgA Nephropathy: A Cohort Study.** Am J Kidney Dis. 2024 Feb 15:S0272-6386(24)00609-7. doi: 10.1053/j.ajkd.2023.12.016. Epub ahead of print. PMID: 38364955.
 28. Floege J. **A new alternative: inhibiting complement activation in patients with IgA nephropathy.** Kidney Int. 2024 Jan;105(1):28-30. doi: 10.1016/j.kint.2023.10.012. PMID: 38182298.
 29. Barratt J, Liew A, Yeo SC, Fernström A, Barbour SJ, Sperati CJ, Villanueva R, Wu MJ, Wang D, Borodovsky A, Badri P, Yureneva E, Bhan I, Cattran D; Cemdisiran Phase 2 Study Investigators and Collaborators. **Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial.** Clin J Am Soc Nephrol. 2024 Apr 1;19(4):452-462. doi: 10.2215/CJN.0000000000000384. Epub 2024 Jan 15. PMID: 38214599.
 30. Jincan Zan, Lijun Liu, Guisen Li, Hongguang Zheng, Nan Chen, Caili Wang, Deqiong Xie, Li Zuo, Rongshan Li, Pengfei Zhang, Yue Wang, Wenxiang Wang, Lin Li, Jianmin Fang, Jicheng Lv, Hong Zhang, **Effect of Telitacicept on Circulating Gd-IgA1 and IgA-Containing Immune Complexes in IgA Nephropathy,** Kidney International Reports, Volume 9, Issue 4, 2024, Pages 1067-1071, ISSN 2468-0249, <https://doi.org/10.1016/j.ekir.2024.01.003>.

31. Zand L, Fervenza FC, Coppo R. **Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients.** Clin Kidney J. 2023 Dec 4;16(Suppl 2):ii19-ii27. doi: 10.1093/ckj/sfad232. PMID: 38053974; PMCID: PMC10695511.
32. Cheung CK, Barratt J, Carroll K, Lafayette RA, Liew A, Suzuki Y, Tesař V, Trimarchi H, Wong MG, Zhang H, Perkovic V, Rizk DV. **Targeting APRIL in the Treatment of IgA Nephropathy.** Clin J Am Soc Nephrol. 2024 Mar 1;19(3):394-398. doi: 10.2215/CJN.0000000000000338. Epub 2023 Oct 6. PMID: 37801688; PMCID: PMC10937009.